MPNs | Clinical

Ruxolitinib’s Role for Symptoms and Survival Benefit in Myelofibrosis

January 04, 2023

During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed data supporting the use of ruxolitinib and what role it may play in improving long-term outcomes for patients with myelofibrosis. This is the second of 2 articles based on this event.